Abstract
The authors review existing models of biomarker dynamics and develop and investigate several new models which may better accommodate the underlying biology. While the general foundations of the models studied could be applied to a number of biomarker systems, the parameter values and specific applications to treatment regimens are focused on the role of prostate-specific antigen (PSA) as a biomarker for prostate cancer. Included are suggestions for possible clinical validation studies.